

The Utility of Serum Biomarkers in Diagnosing Viral Hepatitis Variant in Brazil

Lucas Henrique Moreira¹, Haoyuan Li²

¹ Departamento de Análises Clínicas, Universidade Federal do Paraná (UFPR), Spain

² Faculty of Sports and Health Sciences, Guangxi University for Nationalities, Guangxi Nanning, 530006, China

ABSTRACT

With the remarkable development of hepatitis C curative medicines over the past decade, the management of viral hepatitis has undergone significant changes. Significant developments have also been made in creating and enhancing the HEV and HAV vaccines. Despite these developments, no medications currently can treat hepatitis B or suppress the virus. The research determines the utility of serum biomarkers in diagnosing. The most promising methods for eliminating the virus are gene-silencing technologies and immunomodulatory therapies. However, targeted antiviral medications against HBV are also encouraging future treatments. Targeted antiviral drugs against HDV have been developed in response to the increasing number of HDV cases; these drugs are currently undergoing clinical trials. Ultimately, the primary objective of eradicating viral hepatitis and reducing the burden of these illnesses on the public health system is to achieve optimal screening through comprehensive testing, widespread immunisation, and treatment coverage. The research recommends conducting more serological studies in conjunction with molecular tests that are specifically designed to produce reactive and definitive results. Furthermore, the manifestation of concurrently positive outcomes signifying the existence of IgM antibodies for distinct causative agents does not preclude the potential for a cross-reaction between them.

Keywords: Serum Biomarkers (SBM), Diagnosing Viral Hepatitis (DSH), Brazil (B)

INTRODUCTION

Serum Biomarkers refer to specific types of molecules found in serum that can detect the presence of various viral diseases. Viral hepatitis has been the main concern in the healthcare sector nowadays. The increasing rate of viral hepatitis onset in the world has made people worried about it. As we know, different types of viruses may cause different types of hepatitis in the human body. The swift and timely diagnosis of viral hepatitis is mandatory to make its treatment possible. Otherwise, this viral hepatitis may affect the liver of human beings and can be fatal as well. In this introduction, we will provide an overview of how Serum Biomarkers can be easily utilised in Diagnosing Viral Hepatitis Variants in Brazil [1, 2]. There are different types of serum Biomarkers, such as proteomic, metabolomic, glycemic, and genetic Biomarkers. The recent studies relevant to Brazil have proved that there is a prevalence of hepatitis B and hepatitis C viruses, which have tremendously increased the number of infectious Hepatitis Diseases. Various serum biomarkers can be used to easily and efficiently diagnose these viruses. The first important serum Biomarker is HBsAg, the hepatitis B surface antigen. It can easily be used as a diagnostic marker because this protein is present on the surface of the hepatitis B virus[3]. The primary function of this protein is to attach a virus to the human body and then facilitate the virus's entry into liver cells. Because it is an antigen, it will help the immune system produce antibodies by stimulation. This protein is responsible for the pathogenicity of the hepatitis B virus. The primary benefit of this protein in medical science is that it can aid in diagnosing the presence of the hepatitis B virus in the body. For this purpose, medical diagnostic tests are done, which may indicate the presence or absence of this protein. The presence of this protein indicates the infection of the hepatitis B virus in the body. The other important serum Biomarker is anti-HBs[4]. This is primarily an antibody produced by the immune system in response to the hepatitis B antigen. It means that this is the antibody that develops immunity in the body against the hepatitis B

virus. The primary function of this antibody is to prevent infection in the liver caused by the hepatitis B virus. The presence of this antibody in the body indicates a positive response to vaccination. In medical science, the test related to this antibody can be used to determine the susceptibility of any population to infection with the hepatitis B virus. The other important serum Biomarker for the diagnosis of viral hepatitis is HCV RNA. It is the single-stranded genetic molecule of the hepatitis C virus that is responsible for its pathogenicity [5]. As it is a crucial component of the hepatitis C virus's structure, it can be effectively utilised as a biomarker to identify and diagnose the presence of the virus in the body. This biomarker can also be used to understand the vaccination response in the human body related to the Hepatitis C virus. The presence of this biomarker in the body indicates that the hepatitis C virus infects liver cells. A variety of RNA tests are performed to identify the presence of hepatitis C virus RNA in the body. These important tests include qualitative, quantitative, and genetic-related tests, which confirm the presence of this RNA in the body[6]. The other important serum Biomarker that can be used for the diagnosis of viral hepatitis is HCV. Similar to anti-HBV, anti-HCV is also an antibody produced in the body in response to the antigen of the Hepatitis C virus. When the hepatitis C virus enters the body, the immune system is stimulated, producing antibodies known as anti-HCV. The presence of such antibodies in the body indicates a lower risk of infection from the hepatitis C virus. The presence of this antibody in the body also indicates a positive response to vaccination. As we know, the primary objective of vaccination is to stimulate the body's antibody production. The other most important serum Biomarker, mostly used for diagnosing hepatitis in the body, is ALN[7]. This is an abbreviation of alanine transaminase. It is an important type of enzyme in liver cells that plays a primary role in metabolising amino acids within the liver. As it is evident from medical studies, hepatitis may disrupt the true structure of the liver, so when the structure of the liver becomes

disturbed, the amount of this enzyme is also affected in the liver. In this way, we can utilise this enzyme as a serum biomarker to gauge the liver's health. The lower concentration of this enzyme in the liver indicates that there is some damage to hepatocytes or liver cells. Not only because of viral infection, but this enzyme can also provide information about damage to the liver caused by medications or toxins [8]. The other important Biomarker in serum that can be used for early diagnosis of viral hepatitis is AST, which stands for aspartate transaminase. This is also a type of enzyme that is involved in the metabolism of amino acids. This enzyme is present in the liver, heart, kidneys, and other muscles. The accurate amount of this enzyme can be used to monitor the health of the liver [9]. In the Case of any damage to the liver due to hepatitis, it can be easily assessed by the true concentration of this enzyme. Any abnormality in the concentration of this enzyme indicates damage to the liver. There are various benefits to utilising serum biomarkers for diagnosing viral hepatitis [10]. The first benefit is early detection, the second benefit is an accurate diagnosis, the third benefit is the identification of disease severity, and many others [11, 12].

Research objective

The primary objective of this research is to investigate the use of serum Biomarkers for the early diagnosis of viral hepatitis in Brazil. This study effectively explains the importance of Serum Biomarkers for the early detection of various diseases. The research determines the Utility of Serum Biomarkers in Diagnosing Viral Hepatitis Variants in Brazil. The research paper is divided into five specific sections. The first portion represents the introduction and includes the research objective. The second portion defines the literature review. The third section outlines the research methods. The fourth portion describes the results and their descriptions. The final section summarises the overall research study and presents recommendations on the Utility of Serum Biomarkers in Diagnosing Viral Hepatitis Variants in Brazil.

LITERATURE REVIEW

Researchers claim that cancer-related deaths are increasing due to the wide range of infections associated with hepatitis. The death rate due to HCC has exceeded its limit around the world. The possible surveillance provided to HCC patients is through the use of serum-based biomarkers. AFP is a biomarker given to people of different age groups affected by HCC. For the use of bootmaker serums in HCC, various validations have been conducted at the clinical level in Europe [13]. Studies suggest that the complexity associated with liver disease ultimately results in HCC. The number of viral infections caused by liver infection severity is substantial. Almost twenty-one to forty-two percent of cases of liver infection cause HCV and HBV. The World Health Organisation has developed a clinically based treatment strategy for eliminating the spread of hepatitis and its related variants [14]. Studies show that the variants associated with hepatitis B show phylogenetic features. The diverse phylogenetic linkage observation in hepatitis B patients induces behavioural changes in them. Also, patients with hepatitis B are at higher risk of developing a lesser-known hepatitis D virus [15]. Studies predict that the liver's ability to function properly declines in fulminant hepatitis. HPgV-1 is the pig virus observed in patients with fulminant hepatitis. Little detail is known about the mode of action of the HPgV-1 virus in fulminant hepatitis conditions [16]. Studies explain that the severity of the viral condition prevails in patients affected with DENV. In DENV, the patients undergo two phases

of infection. These phases are primary and secondary. The potential agents behind these infection phases are IFN- α and IFN- γ [17]. Studies predict that chronicity of the hepatitis virus is higher in patients of type D than in type B. Hepatitis B virus patients are at higher risk of getting severe infection from, and thereby, their chances of mortality increase. To assess the chronicity of the hepatitis virus and most variants, cost-effective methods are preferable. The prediction core is a non-invasive method that predicts the likelihood of developing fibrosis in hepatitis patients by providing information in the form of scores [18]. Scholars studies provide evidence that nine genotypic forms of hepatitis B are present. All variants of hepatitis B cause extreme infection in patients that lead to their silent death. The World Health Organisation is working hard to eradicate the deadly variants of the hepatitis virus from the world by the year 2030 [19]. Moreover, there are five main types of viral hepatitis. All five types have their symptoms and result in chronic conditions. A large number of the world's population suffers from public emergency every year due to a sudden increase in hepatitis cases [20]. Studies reveal that during the outbreak of yellow fever in the Brazilian state, the variants of late relapsing hepatitis were identified in patients. Clinical studies predict that the symptoms of late relapsing hepatitis appear within forty to around sixty days [21]. Studies reveal that understanding the correlation between tumour differentiation and HCC requires immunoassay-based research methods. For improved research outcomes, large biomarkers for tumour identification are required during the diagnosing process of HCC [22]. Studies suggest that CD80 shows a good response in children with MCD. Various studies made in Brazil on individuals predict that using CD80, as well as subpar, act as a great biomarker for treating MCD. Still, the actual result of studies confirmed that the specificity of CD80 is not limited to MCD. In contrast, the supar shows no useful treatment or therapeutic ability against MCD [23]. studies were made to investigate the viral antigen responsible for inducing hepatitis E. the results of studies claimed that urine is that viral agent and is involved in causing the complexity related to hepatitis E virus [24]. scholar suggest that prevalence rate of hepatitis A virus is more than half of two million per anum. Many preventable vaccines for hepatitis A have been developed to treat this virus. The main attack made by the hepatitis A virus is on the liver. patients with less to mild liver dysfunction recover while one percent of patients face chronic failure of the liver [25]. Studies reveal that the hepatitis virus can sometimes be inherited. AHP is a hepatitis variant that is a heritable virus and is regarded as a metabolic deregulatory disorder. The primary biomarker agent available for treating AHP is NfL [24]. Studies have shown that several genetic variations contribute to the onset of HCC. The meta-analysis studies on HCC reveal that genetic variations are one of the major reasons behind the complexity of the hepatitis virus [26]. Studies conducted on ANCA-positive individuals reveal that NET serum levels are higher in these individuals. NE-DNA measures this level of serum. NE-DNA test was made on AVV patients having chronic neoplastic disorder.

The results of this study on ANCN-positive individuals reveal that serum NET acts as a biomarker or agent responsible for diagnosing AVV patients [27]. Studies indicate that selenium is a biological agent with nutritional properties. The micronutrients present in selenium make it an agent responsible for treating cancer. The improvement in immune response due to the antioxidant power of selenium holds great importance in clinical terms [27]. Studies predict that with a growing population, the chances of spreading infectious diseases are increasing.

The use of NMR metabolomics is preferred in clinical laboratories to detect infectious or viral diseases, predicting the kind of virus and its mode of action during the viral replication phase [28]. Studies have shown that in some cases, the occurrence of HCC and HBV is common. Hepatitis B virus and hepatocellular carcinoma (HCC) interact at the molecular level. Understanding the complexity caused by these viruses at the molecular level makes the treatment procedure against these viruses easier [28]. Studies explain that recognising the complexity associated with viral agents at an early stage of disease helps develop effective treatment protocols. Each viral agent that causes a specific virus type requires special treatment and medications. The only possible way to save the general public from the viral infection is to develop preventive measures at the public level. Moreover, the timely diagnosis of viral conditions helps to address the patient's needs immediately. The treatment for the hepatitis virus is costly and requires a well-developed medical infrastructure for its administration. To overcome this problem, nanotechnology-based treatment methods for hepatitis have been developed. The most widely used nanostructure in nanotechnology is carbon, which is used in the treatment of viral hepatitis [29].

Methods

The research determines The Utility of Serum Biomarkers in Diagnosing Viral Hepatitis Variants in Brazil. The research study was based on primary data analysis, and to gather the research data, various questions related to the topic were used. For measurement, the research study employed a Smart PLS Algorithm model. The alarming level of hepatitis in the whole world has become a grim aspect for society. The reasons for viral hepatitis are versatile, but the primary concern is the unhygienic conditions and poor quality of drinking water. It has become a pathetic aspect in Brazil. After seeing the increasing level of hepatitis in Brazil, it is concluded that early diagnosis can help in Better and more effective treatment of hepatitis. For this purpose, serum biomarkers are used to diagnose viral hepatitis in Brazil. There are many important implications of using serum Biomarkers for the diagnosis of viral hepatitis, which are described below:

Early diagnosis of hepatitis, differentiation among different variants of hepatitis, Monitoring of liver damage

Viral Hepatitis is caused by different variants of the hepatitis virus, such as hepatitis B virus and hepatitis C virus, among others. The

presence of these viruses can be easily detected by serum biomarkers, which can indicate susceptibility to infection in a given human population. In the case of serum biomarkers, some particular substances act as biomarkers whose presence is related to diseases caused by the hepatitis virus in the body. For example, when the hepatitis B virus enters the body, it contains a special antigen that can act as a biomarker. As we know, medical science has proven that antibodies form in response to specific antigens within the body. For example, in response to an antigen of the hepatitis B virus, the body produces anti-HBV, which develops immunity against the hepatitis B virus. Therefore, this antibody can also serve as a biomarker for the early diagnosis of viral hepatitis in Brazil. The critical implications of serum Biomarkers are that they aid in the early diagnosis of viral hepatitis, making treatment easier, swifter, and more effective. Another important implication of utilising serum Biomarkers for the diagnosis of viral hepatitis is the differentiation among different variants of hepatitis viruses. As we know, various variants can cause hepatitis in the human body. Therefore, it is crucial to utilise biomarkers that can accurately identify the specific type of variant. This is because the entire treatment procedure depends on the accurate detection of the kind of variant. The utilisation of serum Biomarkers for the diagnosis of viral hepatitis can be based on the precise identification of specific molecules in the human body. For example, the presence of anti-HCV in the body indicates that the HCV virus was present in the body. In this Case, such treatment will be provided that is related to the hepatitis C virus, rather than other forms of hepatitis viruses. So, this method of identification is important because it accurately identifies the type of virus that has entered the body and caused hepatitis. Another important implication of using serum biomarkers for diagnosing viral hepatitis in Brazil is the monitoring of liver health. There are specific molecules that provide information about the health of the liver, making them potential biomarkers for diagnosis. For example, there is an enzyme named ALT, which stands for alanine transaminase. The primary function of this enzyme is to metabolize amino acids in liver cells. When any factor causes damage to liver cells, the amount of this enzyme fluctuates, providing information about potential liver damage. In this way, we can say that this biomarker not only aids in the diagnosis of liver hepatitis but also can be used in screening programs. As we know, screening programs are done to determine the susceptibility of any population to a particular disease. When this Biomarker is used for screening, it can provide insight into potential future liver damage. The critical implications of serum Biomarkers for the diagnosis of viral hepatitis convince us that they have their place in medical science (Figure 1).




FIGURE 1: Viral Hepatitis Variant

Tracking of transmission patterns of hepatitis, knowledge of high-risk groups of the population, and evaluation of vaccine efficiency and effectiveness

Medical studies have shown that there are specific transmission patterns for every disease, and these patterns depend on the vectors that carry the virus from one host to another. The other important implication of utilising serum biomarkers for the diagnosis of viral hepatitis is that not only can they help detect hepatitis, but they can also aid in studying the transmission patterns of hepatitis. When transmission patterns of hepatitis are learned well, it can help to take preventive measures in practical ways to reduce the increasing rate of hepatitis. Another important implication of using serum Biomarkers for the diagnosis of viral hepatitis in Brazil is the aspect of identifying high-risk groups within the population. There are some areas in which there is more risk of hepatitis viruses as compared to other places. The reason is that those areas provide suitable conditions for better growth

and replication of these viruses. In this respect, we can say that some groups of the population are at a higher risk of contracting the disease compared to other populations, and these are termed high-risk groups.

The high Risk of disease in these groups is also related to the aspect that these people have less immunity, so there is much susceptibility of these people to hepatitis. The serum biomarkers can help identify three high-risk groups, allowing for effective preventive measures to be taken in these groups. In this way, such groups may get swift treatment in Case of the onset of hepatitis. The other important implication of utilising serum biomarkers for the diagnosis of viral hepatitis in Brazil is the evaluation of vaccine efficiency. As we know, a vaccine is the best way to prevent any disease before it occurs. In the Case of hepatitis, vaccination is administered in order to avoid the disease in humans. As a result of immunisation, specific antibodies in the body can be produced that can act as biomarkers. In this way, these Biomarkers can be used to evaluate the efficiency of any particular vaccine.

Smart PLS Algorithm Model




FIGURE 2: Smart PLS Algorithm Model

The model in Figure 2, referred to as the Smart PLS Algorithm model result, demonstrates that SB-1 exhibits a positive correlation with SB. Its rate is 0.351 and shows a 35% positive and significant relation with them. The SB-1 shows that 0.807, 0.231, and 0.859 indicate 80%, 23%, and 85% positive and significant relations with them. The SB shows a 42% positive and considerable link with VHV. Similarly, the VHV shows that -0.264 is negative, but it has a substantial relation with them. The SB-1 is described as having a 46% positive and significant relation with VHV-1, respectively. The overall graph presents a considerable relation between them. Liver cirrhosis and fibrosis are frequently caused by persistent HCV infection. Non-invasive assays are desperately needed to identify and track liver fibrosis in individuals with long-term HCV infection. Liver biopsy is an expensive and potentially problematic operation despite being the gold standard for evaluating liver fibrosis. The use of non-invasive serum biomarkers as a substitute for liver biopsies has been studied. Several serum markers, such as

haptoglobin, alpha2-macroglobulin, apolipoprotein A1, gamma-glutamyl transpeptidase, and bilirubin, have been found to have positive predictive values for liver fibrosis in hepatitis C patients. These noninvasive approaches for assessing liver fibrosis biomarkers are used in these serum markers, which are sold under the names Fibro Test and Fibro Scan. The diagnostic test accuracy of Fibro Test and Fibro Scan suggests that they may be able to detect fibrosis/cirrhosis associated with HCV; however, their accuracy for fibrosis in earlier stages is reduced. Regardless of therapy, Fibro Test has a greater 5-year prognostic value than biopsy estimations when compared to liver biopsies. Its risk variables are similarly comparable to those of liver biopsies. The identification of chronic hepatitis C patients with fibrosis and cirrhosis is facilitated by additional non-invasive indicators, such as the aspartate aminotransferase (AST) to platelet ratio index (APRI) and FIB-4 index, which combines conventional biochemical values (platelets, ALT, and AST) with age.

TABLE 1: Descriptive Statistics

Name	No.	Mean	Median	Scale min	Scale max	Standard deviation	Excess kurtosis	Skewness	Cramér-von Mises p value
SB1	1	1.720	2.000	1.000	3.000	0.634	-0.626	0.321	0.000
SB2	2	1.600	2.000	1.000	3.000	0.663	-0.565	0.678	0.000
SB3	3	1.680	2.000	1.000	4.000	0.733	0.585	0.913	0.000
SB4	4	1.740	2.000	1.000	3.000	0.626	-0.585	0.267	0.000
SB5	5	1.660	2.000	1.000	4.000	0.710	0.947	0.961	0.000
VHV1	6	1.580	2.000	1.000	3.000	0.603	-0.574	0.528	0.000
VHV2	7	1.720	2.000	1.000	4.000	0.722	0.572	0.821	0.000
VHV3	8	1.640	2.000	1.000	3.000	0.656	-0.641	0.553	0.000
VHV4	9	1.700	2.000	1.000	3.000	0.640	-0.651	0.377	0.000
VHV5	10	1.600	2.000	1.000	3.000	0.632	-0.556	0.587	0.000
VHV6	11	1.840	2.000	1.000	4.000	0.857	-0.305	0.715	0.000

The results in Table 1, as shown in the descriptive statistics, demonstrate the mean value, median rate, minimum value, standard deviation, skewness value, and probability rate for each variable. SB1, 2, 3, 4, and 5 results show that the mean values are 1.720, 1.600, 1.680, 1.740, and 1.660. All of them show the positive average values of the mean. The standard deviation rates are 63%, 66%, 73%, 62%, and 71% deviation from the mean values. The result demonstrates that the overall significant rate is 0.000. The skewness values are 32%, 67%, 91%, 26%, and 96%, representing a skewness rate of 32%, 67%, 91%,

26%, and 96%, respectively. The VHV1, 2, 3, 4, 5, and 6 are all factors considered dependent variables. The results indicate that the mean values are 1.580, 1.720, 1.640, 1.700, 1.600, and 1.840. All of them show positive average values of the mean. The results indicate that the standard deviation rates of each variable are 72%, 65%, 64%, and 63%, and that 85% deviate from the mean values. According to the above result, the skewness values are 82%, 55%, 37%, 58%, and 71%, representing a skewness rate of 82%, 55%, 37%, 58%, and 71% between them (Figure 3).




Figure 3: Serum Biomarkers in Diagnosing Viral Hepatitis

Table 2: Correlation Coefficient Analysis

	SB1	SB2	SB3	SB4	SB5	VHV1	VHV2	VHV3	VHV4	VHV5	VHV6
SB1	1.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
SB2	0.114	1.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
SB3	0.195	-0.140	1.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
SB4	0.320	0.568	-0.007	1.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
SB5	0.322	-0.076	0.482	-0.019	1.000	0.000	0.000	0.000	0.000	0.000	0.000
VHV1	0.373	0.180	0.058	0.029	-0.100	1.000	0.000	0.000	0.000	0.000	0.000
VHV2	0.091	0.017	0.397	-0.028	0.321	-0.040	1.000	0.000	0.000	0.000	0.000
VHV3	0.094	0.175	-0.073	0.308	0.081	-0.180	-0.002	1.000	0.000	0.000	0.000
VHV4	0.089	-0.330	0.009	0.055	0.215	-0.378	-0.095	-0.019	1.000	0.000	0.000
VHV5	-0.080	0.191	-0.535	0.192	-0.214	0.136	-0.289	0.039	-0.148	1.000	0.000
VHV6	0.175	0.063	0.237	-0.003	0.436	-0.014	0.154	0.075	0.058	-0.118	1.000

The correlation coefficient study results, as shown in Table 2, regarding the usefulness of serum biomarkers in diagnosing viral hepatitis variations, are depicted in the table above. The outcome demonstrates both positive and negative relationships between them. Viral hepatitis is a significant public health problem because it can become chronic and lead to the development of end-stage liver disease or hepatocellular carcinoma (HCC). Consequently, one of the most frequent reasons for liver transplantation is viral hepatitis, which exacerbates the imbalance between the supply and demand for donor organs. Hepatitis A and E typically manifest as a self-limiting course that resolves in full recovery. Still, hepatitis B and C can cause chronic infection and are responsible for the severe symptoms of this illness. According to estimations from the World Health Organisation (WHO), 71 million people globally have HCV viremia and 100 million people have an antibody against the hepatitis C virus (HCV). A multicenter global study measuring the prevalence of the hepatitis B virus (HBV) surface antigen (HBsAg) involved 3.61% of participants from 161 countries. Due to their significant prevalence, the WHO has established a goal to eliminate hepatitis B and C by 2030. Improving antiviral therapy alternatives and streamlining methods to halt the spread of illness are among these objectives. Significant and rapid progress has been made in the diagnosis, treatment, and control of viral hepatitis over the last decade. Despite these advancements, issues with the diagnosis, referral, screening, and treatment of viral hepatitis persist. Because of the severe consequences of viral hepatitis and its high

incidence, research in this field has always been intense, leading to the gradual evolution of new and more effective treatments. This research aims to provide a comprehensive review of the literature on the management of viral hepatitis, with a focus on clinical care. Comprehensive descriptions are provided of additional interesting research issues and their future therapeutic applications.

Conclusion

We could conclude that serum biomarkers can function as useful diagnostic tools for various forms of hepatitis after reviewing the significant implications of serum biomarkers for the diagnosis of viral hepatitis in Brazil. This work led to an improvement in the effectiveness of the quality management system and a reduction in the critical stages of the organisational process through internal audits that prioritised risk management. More attention is needed for patients who co-infect with HBV and HCV. Those who test positive for HBsAg or anti-HBc should be constantly monitored while receiving HCV medication. Further study addressing immunological serum markers should be carried out to enhance epidemiological surveillance in treatment trials and correlate the natural history of hepatitis virus infections with outcomes (HBeAg seroconversion and HBsAg serum clearance). In addition, the antiviral therapy for hepatocellular carcinoma (HCC) considers the changing challenges associated with genomic surveillance of tumours, as well as the anticipated genetic

characteristics related to the emergence and progression of liver lesions and damage in these chronic patients. Conclusion: Based on the study's findings, the authors concluded that serological markers of viral infections are crucial for both screening and monitoring individuals who are asymptomatic. These individuals are often ignored despite being viral carriers. To determine whether a connection exists between the viruses in any given instance, cases with a positive viral load from hepatitis infections must also be carefully examined. Dra. Simões

investigated enhancing the vaccination model of heterological antigens based on hepatitis B viral envelope protein, incorporating HCV antigen as a chimeric vaccine, to advance the development of hepatitis genetic engineering. A new study on immunological serum indicators should be further investigated to connect the natural history of hepatitis virus infections with hepatocellular carcinoma (HCC), aiming to improve cancer genomic and epidemiological surveillance in therapeutic trials.

References

- [1] I. F. Rodart *et al.*, "Diagnostic accuracy of serum hyaluronan for detecting HCV infection and liver fibrosis in asymptomatic blood donors," *Molecules*, vol. 26, no. 13, p. 3892, 2021.
- [2] D. A. Yela, M. Faber, A. Dantas, C. L. Benetti-pinto, and R. Jales, "Difficulty in Diagnosing of Renal Choriocarcinoma: Case Report," *Jornal Brasileiro de Patologia e Medicina Laboratorial*, vol. 58, 2022.
- [3] E. M. Janahi *et al.*, "Hepatitis B virus genotypes in the Kingdom of Bahrain: prevalence, gender distribution and impact on hepatic biomarkers," *Medicina*, vol. 55, no. 10, p. 622, 2019.
- [4] A. C. d. Silva Souza *et al.*, "Identification of hepatitis B virus A1762T/G1764A double mutant strain in patients in Southern Brazil," *Brazilian Journal of Infectious Diseases*, vol. 21, no. 5, pp. 525-529, 2017.
- [5] C. N. Correia *et al.*, "Circulating microRNAs as potential biomarkers of infectious disease," *Frontiers in immunology*, vol. 8, p. 118, 2017.
- [6] J.-P. Allain and O. Opare-Sem, "Screening and diagnosis of HBV in low-income and middle-income countries," *Nature reviews Gastroenterology & hepatology*, vol. 13, no. 11, pp. 643-653, 2016.
- [7] O. C. Araujo, V. S. de Paula, K. M. do Ó, C. A. Villela-Nogueira, and N. M. Araujo, "Association of Polymorphisms in the Glutathione S-Transferase Theta-1 gene with cirrhosis and hepatocellular carcinoma in Brazilian patients with chronic hepatitis C," *Vaccines*, vol. 9, no. 8, p. 831, 2021.
- [8] C. M. Croagh, P. V. Desmond, and S. J. Bell, "Genotypes and viral variants in chronic hepatitis B: A review of epidemiology and clinical relevance," *World journal of hepatology*, vol. 7, no. 3, p. 289, 2015.
- [9] A. M. Santiago *et al.*, "TNFA-308G> A and IL10-1082A> G polymorphisms seem to be predictive biomarkers of chronic HCV infection," *BMC Infectious Diseases*, vol. 21, pp. 1-8, 2021.
- [10] L. M. Villar, H. M. Cruz, J. R. Barbosa, C. S. Bezerra, M. M. Portilho, and L. de Paula Scalioni, "Update on hepatitis B and C virus diagnosis," *World journal of virology*, vol. 4, no. 4, p. 323, 2015.
- [11] E. d. S. G. Amorás *et al.*, "The Genetic Profile and serum level of IL-8 are Associated with Chronic Hepatitis B and C Virus infection," *Biomolecules*, vol. 11, no. 11, p. 1664, 2021.
- [12] G. R. Ubillus, C. R. Neira-Montoya, E. E. Sedano-Gelvet, and J. F. Verona-Cueva, "New algorithm to differentiate histochemical types of intestinal metaplasia: G&S2 method," *Jornal Brasileiro de Patologia e Medicina Laboratorial*, vol. 58, 2022.
- [13] B. J. Beudeker *et al.*, "Validation and optimization of AFP-based biomarker panels for early HCC detection in Latin America and Europe," *Hepatology Communications*, vol. 7, no. 10, p. e0264, 2023.
- [14] L. Bucio-Ortiz *et al.*, "Occult Hepatitis B Virus Infection in Hepatic Diseases and Its Significance for the WHO's Elimination Plan of Viral Hepatitis," *Pathogens*, vol. 13, no. 8, p. 662, 2024.
- [15] G. M. Castro *et al.*, "Acute and chronic HBV infection in central Argentina: High frequency of sub-genotype F1b, low detection of clinically relevant mutations and first evidence of HDV," *Frontiers in Medicine*, vol. 9, p. 1057194, 2023.
- [16] A. S. da Silva *et al.*, "Human pegivirus-1 detection and genotyping in brazilian patients with fulminant hepatitis," *Pathogens*, vol. 12, no. 9, p. 1122, 2023.
- [17] T. B. de Arruda *et al.*, "Viremia and Inflammatory Cytokines in Dengue: Interleukin-2 as a Biomarker of Infection, and Interferon- α and- γ as Markers of Primary versus Secondary Infection," *Pathogens*, vol. 12, no. 11, p. 1362, 2023.
- [18] L. I. Grecu *et al.*, "Non-Invasive Prediction Scores for Hepatitis B Virus-and Hepatitis D Virus-Infected Patients—A Cohort from the North-Eastern Part of Romania," *Microorganisms*, vol. 11, no. 12, p. 2895, 2023.
- [19] A. Panduro, S. Roman, S. Laguna-Meraz, and A. Jose-Abrego, "Hepatitis B virus genotype H: epidemiological, molecular, and clinical characteristics in Mexico," *Viruses*, vol. 15, no. 11, p. 2186, 2023.
- [20] M. D. Pauly and L. Ganova-Raeva, "Point-of-Care Testing for Hepatitis Viruses: A Growing Need," *Life*, vol. 13, no. 12, p. 2271, 2023.
- [21] I. M. d. Rezende *et al.*, "Characterization and investigation of risk factors for Late-relapsing hepatitis after yellow fever," *Clinical Infectious Diseases*, vol. 77, no. 4, pp. 565-573, 2023.
- [22] M. Tufael *et al.*, "Correlation Between Tumor Differentiation and Biomarkers in Hepatocellular Carcinoma: Implications for Early Diagnosis and Treatment," 2024.
- [23] R. d. C. Zen *et al.*, "Urinary CD80 and serum suPAR as biomarkers of glomerular disease among adults in Brazil," *Diagnostics*, vol. 13, no. 2, p. 203, 2023.
- [24] D. Ying *et al.*, "Urine is a viral antigen reservoir in hepatitis E virus infection," *Hepatology*, vol. 77, no. 5, pp. 1722-1734, 2023.
- [25] P. Van Damme, R. M. Pintó, Z. Feng, F. Cui, A. Gentile, and D. Shouval, "Hepatitis A virus infection," *Nature Reviews Disease Primers*, vol. 9, no. 1, p. 51, 2023.
- [26] A. P. Mesquita *et al.*, "Gene variations related to the hepatocellular carcinoma: Results from a field synopsis and Bayesian reevaluation," *Gene*, vol. 869, p. 147392, 2023.
- [27] P. I. d. S. O. Menezes, F. P. Veras, F. de Queiroz Cunha, L. M. da Silva, P. Louzada-Júnior, and R. D. R. Oliveira, "Measurement of Neutrophil Extracellular Traps as a Biomarker for the Differential Diagnosis Between Antineutrophil Cytoplasmic Antibody–Positive Individuals With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis and Nonautoimmune Diseases," *JCR: Journal of Clinical Rheumatology*, vol. 30, no. 3, pp. 94-100, 2024.
- [28] Y. Min *et al.*, "Hepatitis B virus infection: An insight into the clinical connection and molecular interaction between hepatitis B virus and host extrahepatic cancer risk," *Frontiers in Immunology*, vol. 14, p. 1141956, 2023.
- [29] A. Gholami *et al.*, "Advanced Theranostic Strategies for Viral Hepatitis Using Carbon Nanostructures," *Micromachines*, vol. 14, no. 6, p. 1185, 2023.



This is an open-access article distributed under the terms of the Creative Commons Attribution License.